Clinical trial B9991025
Phase 1b/2 study to evaluate safety and anti-tumor activity of Avelumab in combination with the poly (adenosine diphosphate [adp]-ribose) polymerase (PARP) inhibitor Talazoparib in patients with locally advanced or metastatic solid tumors
| Organ | Multiple |
|---|---|
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Pfizer |
| EudraCT Identifier | 2017-001509-33 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03330405 |
| Inclusion criteria | Biopsy |
| Last update |